Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XanaHES: Safety of Xanamem in Healthy Elderly Subjects
NCT03830762Phase 1Completed
- Sponsor
- Actinogen Medical Limited
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of emestedastat in Alzheimer's disease (AD) (3 arms), sponsored by Actinogen Medical Limited. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 20 weeks, Incidence of Clinically Significant Changes in Serum Biomarker Levels at 16 weeks and 9 more. Started Jan 2019; status: completed.
02
Drugs
emestedastat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03830762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830762.